【Lotus Pharmaceutical】Announcement of the Board of Directors' Resolution to Approve the 2026 First Quarter Financial Report

1. Date of submission to the board of directors or resolution by the board of directors: 2026/05/11 2. Date of approval by the audit committee: 2026/05/08 3. Reporting period for financial report or self-compiled financial information Start and end dates (YYYY/MM/DD~YYYY/MM/DD): 2026/01/01 ~ 2026/03/31 4. Cumulative operating revenue from January 1 to the end of this period (in thousands of NTD): 8,644,409 5. Cumulative operating gross profit (loss) from January 1 to the end of this period (in thousands of NTD): 4,385,622 6. Cumulative operating income (loss) from January 1 to the end of this period (in thousands of NTD): 1,959,197 7. Cumulative pre-tax net profit (loss) from January 1 to the end of this period (in thousands of NTD): 725,899 8. Cumulative net profit (loss) for this period from January 1 to the end of this period (in thousands of NTD): 567,201 9. Cumulative net profit (loss) attributable to owners of the parent company from January 1 to the end of this period (in thousands of NTD): 567,201 10. Cumulative basic earnings per share (loss) from January 1 to the end of this period (in NTD): 2.18 11. Total assets at the end of the period (in thousands of NTD): 107,533,585 12. Total liabilities at the end of the period (in thousands of NTD): 83,501,410 13. Equity attributable to owners of the parent company at the end of the period (in thousands of NTD): 24,032,175 14. Other matters to be specified: None Keywords: Material Information